Azenta, Inc.

Azenta, Inc.(AZTA)股票分析

$36.520

-0.650 (-1.78%)收盘时

Loading chart…
最高
37.110
开盘
36.950
成交量加权均价
36.28
成交量
1.22M
市值
2.81B
最低
35.195
成交额
44.16M
企业价值/息税折旧摊销前利润(TTM)
36.27

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software.

AI 分析 of Azenta, Inc. (AZTA)

持有

Azenta Inc is currently a hold. The stock is priced at $37.72, which is above the analyst price target of $35, indicating potential overvaluation. The recent RSI of 56.115 suggests that the stock is neither overbought nor oversold, but the negative sentiment from ongoing investigations into securities claims could pose risks.

估值指标

Azenta, Inc.(AZTA)当前预期市盈率为 29.07,5 年平均预期市盈率为 186.89。

预期市盈率

合理
5 年均值 P/E
186.89
当前P/E
29.07
高估
487.57
低估
-113.79

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
29.76
当前EV/EBITDA
36.27
高估
68.18
低估
-8.66

预期市销率

合理
5 年均值 P/S
4.87
当前P/S
2.55
高估
8.08
低估
1.66

Alphio AI 对 AZTA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AZTA

$34.77

情景价格

基

基准

基准 · 50%AZTA

$30.40

情景价格

悲

悲观

悲观 · 25%AZTA

$25.27

情景价格

持有 AZTA 的大户

A

American Capital Management, Inc.

+ 持有AZTA

+3.92%

3个月收益率

事件时间线

2026-08-24 (ET)

08:30:00

Company Reaffirms Q4 Total Revenue Guidance

08:30:00

Azenta Appoints Martin Madaus as Interim CEO

2026-08-04 (ET)

17:00:00

Company Q3 Revenue Exceeds Expectations at $161M

17:00:00

Company Expects Organic Revenue Flat to Up 1% for FY2025

17:00:00

Total Organic Revenue Expected to Decline in Q4 FY2025

资讯

AZTA 常见问题 —— 由 Alphio AI 解答

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software. It operates in the Healthcare sector (SPECIAL INDUSTRY MACHINERY, NEC industry).

Azenta Inc is currently a hold. The stock is priced at $37.72, which is above the analyst price target of $35, indicating potential overvaluation. The recent RSI of 56.115 suggests that the stock is neither overbought nor oversold, but the negative sentiment from ongoing investigations into securities claims could pose risks.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易